CH \$140.00 218804

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM332493

NATURE OF CONVEYANCE: RELEASE OF SECURITY INTEREST

CONVEYING PARTY DATA

| Name | Formerly | Execution Date | Entity Type |
|------------------------------------|---|----------------|--------------|
| GE Business Capital Corporation | FORMERLY Transamerica Business Credit Corporation | 12/02/2010 | CORPORATION: |

RECEIVING PARTY DATA

| Name: | Dendreon Corporation |
|-----------------|-----------------------|
| Street Address: | 1301 2nd Avenue |
| City: | Seattle |
| State/Country: | WASHINGTON |
| Postal Code: | 98101 |
| Entity Type: | CORPORATION: DELAWARE |

PROPERTY NUMBERS Total: 5

| Property Type | Number | Word Mark |
|----------------------|---------|-----------|
| Registration Number: | 2188041 | DACS |
| Registration Number: | 2530065 | DENDREON |
| Registration Number: | 2465920 | DENDREON |
| Registration Number: | 3616391 | DENDREON |
| Registration Number: | 2545242 | PROVENGE |

CORRESPONDENCE DATA

Fax Number: 2127352000

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 212-735-2811

Email: mribando@skadden.com

Correspondent Name: Skadden, Arps, Slate, Meagher & Flom

Address Line 1: Four Times Square
Address Line 2: Monique L. Ribando

Address Line 4: New York, NEW YORK 10036

| ATTORNEY DOCKET NUMBER: | 180680.3 |
|-------------------------|----------------------|
| NAME OF SUBMITTER: | Monique L. Ribando |
| SIGNATURE: | /Monique L. Ribando/ |

| DATE SIGNED: | 02/18/2015 | |
|--|----------------------|--|
| Total Attachments: 7 | | |
| source=GE Transamerica Security Rele | ase Signed#page1.tif | |
| source=GE Transamerica Security Release Signed#page2.tif | | |
| source=GE Transamerica Security Release Signed#page3.tif | | |
| source=GE Transamerica Security Release Signed#page4.tif | | |
| source=GE Transamerica Security Release Signed#page5.tif | | |
| source=GE Transamerica Security Release Signed#page6.tif | | |
| source=GE Transamerica Security Release | ase Signed#page7.tif | |

RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Agreement is entered into as of this 2nd day of December, 2010, and effective as of February 28, 2004 ("Effective Date"), between GF Business Capital Corporation, formerly known as Transamerica Business Capital Corporation, as successor in interest to Transamerica Business Credit Corporation ("Secured Party") and Dendreon Corporation ("Company").

RECITALS

- A. Secured Party and Company entered into the Intellectual Property Security Agreement, dated as of August 3, 1999 and the Supplement One to Intellectual Property Security Agreement, dated as of June 6, 2001 (collectively, the "Existing IP Agreement"), pursuant to which Company granted a security interest in favor of Secured Party in and to the Intellectual Property Collateral (as defined in the Existing IP Agreement).
- B. Company desires that Secured Party release its security interest in and to the Intellectual Property Collateral upon the terms and conditions set forth in this Agreement.

Therefore, in consideration of these Recitals, any sums to be paid, any rights granted, and the mutual promises contained in this Agreement, the parties agree to the following:

1. RELEASE

1.1 Secured Party, without recourse, representation, warranty or other assurance of any kind, hereby releases and terminates its security interest in the Intellectual Property Collateral, as more particularly described on Exhibits A and B hereto.

2. SECURED PARTY'S REPRESENTATIONS

2.1 Secured Party makes no representations, warranties or other assurances of any kind. In particular, there are no express or implied warranties: (a) of merchantability or fitness for a

particular purpose; or (b) that use of the Intellectual Property Collateral does not infringe any existing trademarks, patents or other intellectual property rights. In addition, nothing in this Agreement may be deemed to be a representation or warranty by Secured Party of the validity of any trademarks and/or trademark applications, patents and/or patent applications or the accuracy, safety, efficacy, or usefulness, for any purpose, of the trademarks and/or trademark applications, patents and/or patent applications constituting Intellectual Property Collateral. Secured Party has no obligation, express or implied, to supervise, monitor, review or otherwise assume responsibility for the production, manufacture, testing, marketing or sale of any product or service. Secured Party has no liability whatsoever to Company, or any third parties, for or on account of any injury, loss, or damage, of any kind or nature, sustained by, or any damage assessed or asserted against, or any other liability incurred by or imposed upon Company or any other person or entity, arising out of or in connection with or resulting from:

- (i) the production, use, practice, lease, or sale of any product or service;
- (ii) the use of the rights granted to Company herein; or
- (iii) any advertising or other promotional activities with respect to any of the foregoing.

3. MISCELLANEOUS

3.1 This Agreement is entered into in the State of Illinois and must be interpreted in accordance with and its performance governed by the laws of the State of Illinois without reference to its conflicts of laws provisions.

[This space left blank intentionally.]

US2000 10536573 1

4 - Entire Understanding

4.1 This Agreement represents the entire understanding between the parties, and supersedes all other agreements, express or implied, between the parties concerning the subject matter hereof, and is not subject to any change or modification except by the execution of a written instrument subscribed to by authorized representatives of the parties.

IN WITNESS WHEREOF, the parties have executed this Agreement as of December 2, 2010.

Secured Party:

GE BUSINESS CAPITAL CORPORATION (FORMERLY KNOWN AS TRANSAMERICA BUSINESS CAPITAL CORPORATION, AS SUCCESSOR IN INTEREST TO TRANSAMERICA BUSINESS CREDIT CORPORATION)

Name: Scott Towers

Title: Duly Authorized Signatory

Company:

DENDREON CORPORATION

Name: Richard F. Hamm, JY.
Title: SR, Grande Development, GC & Secretary

G82000 R6636773 3

 $\underline{\text{Exhibit } \textbf{A}}$ Trademarks and Trademark Applications

| Country | Trademark | Application/Registration No. |
|--------------------|-----------|------------------------------|
| United States | DACS | 2,188,041 |
| United States | DENDREON | 75/283,623 |
| United States | DENDREON | 76/165,904 |
| United States | DENDREON | 75/282,526 |
| United States | MYLOVENGE | 76/028,099 |
| United States | MYEZENIUM | 75/927,065 |
| United States | NEUVENGE | 76/009,430 |
| United States | NEUZENIUM | 75/927,050 |
| United States | PROVENGE | 75/927,064 |
| United States | PROZENIUM | 75/906,694 |
| Canada | MYLOVENGE | 1,071,645 |
| Canada | PROVENGE | 1,071,470 |
| European Community | MYLOVENGE | 1,817.899 |
| European Community | PROVENGE | 1,816,974 |

Exhibit B

Patents and Patent Applications

| Title | Filing Date | Application | Country | Patent No. |
|--------------------------------------|-------------|-------------|---------------|--------------|
| A (DELIAND FOR LY INJOHO) CO CONTACT | 00.21.100.1 | No. | 1 | - 171 (07 |
| METHODS FOR ENRICHING CD34+ | 08-31-1994 | 08/299,469 | United States | 5,474.687 |
| HUMAN HEMATOPOIETIC PROGENITOR | | | | |
| CELLS | 12 11 1005 | 00/570 207 | 11 1 10 | 5.662.051 |
| SEPARATION APPARATUS AND METHOD | 12-11-1995 | 08/570.397 | United States | 5,663.051 |
| REAGENT FOR CELL SEPARATION | 04-09-1986 | 06/849,819 | United States | 4,927,749 |
| CELL SEPARATION PROCESS | 03-25-1987 | 07/049.863 | United States | 4.927.750 |
| CENTRIFUGATION SYRINGE, SYSTEM | 08-31-1994 | 08/298,882 | United States | 5,577,513 |
| AND METHOD | | | | |
| METHODS FOR ENRICHING FETAL | 08-31-1994 | 08/299,468 | United States | 5,646,004 |
| CELLS FROM MATERNAL BODY FLUIDS | | | | |
| METHODS FOR ENRICHING SPECIFIC | 08-31-1994 | 08/299,467 | United States | 5,840.502 |
| CELL-TYPES BY DENSITY GRADIENT | | | | |
| CENTRIFUGATION | | | | |
| METHODS FOR ENRICHING BREAST | 08-31-1994 | 08/299,465 | United States | 5.648,223 |
| TUMOR CELLS | | | | |
| POTENT ANTIGEN PRESENTING CELL | 07-12-1995 | 08/501,987 | United States | 6,121,044 |
| COMPOSITION | | | | |
| CELL SEPARATION COMPOSITION | 12-11-1995 | 08/570.120 | United States | 5.789,148 |
| IMMUNOSTIMULATORY METHOD | 12-28-1995 | 08/579.823 | United States | 6.080,409 |
| IMMUNOSTIMULATORY COMPOSITION | 03-21-1997 | 08/823.008 | United States | |
| AND METHOD | | | | |
| IMMUNOSTIMULATORY | 9-3-1998 | 09/146,283 | United States | 5,976,546 . |
| COMPOSITIONS | | | | |
| IMMUNOSTIMULATORY COMPOSITION | 06-24-1999 | 09/344,195 | United States | 6.210,662 |
| GROWTH ARREST GENE | 06-27-1997 | 08/883,070 | United States | 5.998,599 |
| COMPOSITIONS AND METHODS | | | | |
| CELL WASHING DEVICE AND METHOD | 07-17-1998 | 09/118.326 | United States | 6,197,579 |
| COMPOSITION AND METHOD FOR | 3-14-2000 | 09/402.845 | United States | |
| INDUCING AN IMMUNE RESPONSE | | | | |
| AGAINST TUMOR-RELATED ANTIGENS | | | | |
| PROCESS FOR MAKING SILANIZED | 01-14-1998 | 09/006.775 | United States | 6,015,843 |
| COLLOIDAL SILICA | | <u> </u> | | |
| PROSTATE TUMOR POLYNUCLEOTIDE | 07-09-1998 | 09/112,096 | United States | 6.194,152 |
| COMPOSITIONS AND METHODS OF | | ļ | | |
| DETECTION THEREOF | 06.01.1000 | 100/222 222 | | |
| METHOD FOR PREPARATION AND IN | 06-01-1998 | 09/323,880 | United States | |
| VIVO ADMINISTRATION OF ANTIGEN | | | | |
| PRESENTING CELL COMPOSITION | 00.20.1000 | (0/000 202 | 11.2.15 | |
| SELECTIVE APOPTOSIS OF NEOPLASTIC | 08-28-1998 | 60/098,292 | United States | |

| Title | Filing Date | Application No. | Country | Patent No. |
|-----------------------------------|-------------|-----------------|----------------|---|
| CELLS BY AN HLA-DR SPECIFIC | | | | |
| MONOCLONAL ANTIBODY | | | | |
| SELECTIVE APOPTOSIS OF NEOPLASTIC | 08-26-1999 | 09/383,663 | United States | |
| CELLS BY AN HLA-DR SPECIFIC | | Í | | |
| MONOCLONAL | | | | |
| COMPOSITIONS AND METHODS FOR | 12-14-1998 | 60/112,324 | United States | |
| ENHANCEMENT OF MAJOR | | | | |
| HISTOCOMPATIBILITY COMPLEX | | | | |
| CLASS I RESTRICTED ANTIGEN | | | | |
| PRESENTATION | | | | |
| COMPOSITIONS AND METHODS FOR | 12-14-1999 | 09/461,684 | United States | 7,148,324 |
| ENHANCEMENT OF MAJOR | | | | ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, |
| HISTOCOMPATIBILITY COMPLEX | | | | |
| CLASS I RESTRICTED ANTIGEN | | | | |
| PRESENTATION | | | | |
| SUPPRESSOR AND PROGENITOR CELLS | 11-04-1992 | 07/971,723 | United States | 5,985,656 |
| SUPPRESSOR AND PROGENITOR CELLS | 11-16-1999 | 09/442,171 | United States | |
| SUPPRESSOR CELLS | 08-17-1992 | 07/931.210 | United States | |
| METHODS FOR IN VIVO T CELL | 12-20-1995 | 08/575.432 | United States | |
| ACTIVATION BY ANTIGEN-PULSED | | | | |
| DENDRITIC CELLS | | | | |
| METHODS FOR USING DENDRITIC | 9-6-1994 | 08/301.157 | United States | |
| CELLS TO ACTIVATE T CELLS | | | | |
| METHODS FOR IN VIVO T CELL | 12-20-1995 | 08/575,432 | United States | |
| ACTIVATION BY ANTIGEN-PULSED | 12 20 1372 | 00/3/0,/32 | | |
| DENDRITIC CELLS | į | | | |
| METHODS FOR USING DENDRITIC | 12-01-1993 | 08/160.571 | United States | |
| CELLS TO ACTIVATE GAMMA/DELTA-T | 12 01 1773 | 00,100,571 | omica otates | |
| CELL RECEPTOR-POSITIVE T CELLS | | | | |
| METHODS FOR USING DENDRITIC | 02-28-1996 | 08/610,195 | United States | 6.821.778 |
| CELLS TO ACTIVATE GAMMA/DELTA-T | 02 20 .,,, | 30,0,0,0 | omited offices | 0.0210 |
| CELL RECEPTOR-POSITIVE T CELLS | | | | |
| IDIOTYPIC VACCINATION AGAINST B | 03-14-1990 | 07/493,511 | United States | |
| CELL LYMPHOMA | 03 11 1370 | 07775,511 | Omica states | |
| GENERATION AND | 10-8-1999 | 60/158,618 | United States | |
| CHARACTERIZATION OF A DENDRITIC | 10 0 1333 | 00/150,010 | Officed States | |
| CELL ISOLATED FROM HUMAN | | | , | |
| PERIPHERAL BLOOD MONONUCLEAR | | | | |
| CELLS | | | | |
| GENERATION AND | 10-6-2000 | 09/684,308 | United States | |
| CHARACTERIZATION OF A DENDRITIC | | | | 1 |
| CELL ISOLATED FROM HUMAN | | | | |
| PERIPHERAL BLOOD MONONUCLEAR | | | | 1 |
| CELLS | | | | 1 |

US2000 10536573 1

Page 7

| Title | Filing Date | Application No. | Country | Patent No. |
|---|-------------|-----------------|---------------|------------|
| CRYOPRESERVATION OF ANTIGEN- | 12-3-1999 | 60/168,991 | United States | |
| LOADED DENDRITIC CELLS AND THEIR | | | | |
| PRECURSORS IN SERUM-FREE MEDIA | 12 1 2000 | 00/300 /04 | 11 : 10 | |
| CRYOPRESERVATION OF ANTIGEN- | 12-1-2000 | 09/728,424 | United States | |
| LOADED DENDRITIC CELLS AND THEIR PRECURSORS IN SERUM-FREE MEDIA | | | | |
| COMPOSITIONS AND METHODS FOR | 3-30-2000 | 60/193,504 | United States | |
| DENDRITIC CELL-BASED | | · | | |
| IMMUNOTHERAPY | | | | |
| COMPOSITIONS AND METHODS FOR | 3-30-2001 | 09/821,883 | United States | 7.060,279 |
| DENDRITIC CELL-BASED | | | | |
| IMMUNOTHERAPY | | | | |

US2000 10536573 1

RECORDED: 02/18/2015